1. Home
  2. CSBR vs CABA Comparison

CSBR vs CABA Comparison

Compare CSBR & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSBR
  • CABA
  • Stock Information
  • Founded
  • CSBR 1985
  • CABA 2017
  • Country
  • CSBR United States
  • CABA United States
  • Employees
  • CSBR N/A
  • CABA N/A
  • Industry
  • CSBR Biotechnology: Biological Products (No Diagnostic Substances)
  • CABA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CSBR Health Care
  • CABA Health Care
  • Exchange
  • CSBR Nasdaq
  • CABA Nasdaq
  • Market Cap
  • CSBR 113.0M
  • CABA 118.8M
  • IPO Year
  • CSBR 1986
  • CABA 2019
  • Fundamental
  • Price
  • CSBR $5.87
  • CABA $1.87
  • Analyst Decision
  • CSBR Strong Buy
  • CABA Strong Buy
  • Analyst Count
  • CSBR 1
  • CABA 9
  • Target Price
  • CSBR $12.00
  • CABA $20.33
  • AVG Volume (30 Days)
  • CSBR 30.6K
  • CABA 2.3M
  • Earning Date
  • CSBR 07-17-2025
  • CABA 05-15-2025
  • Dividend Yield
  • CSBR N/A
  • CABA N/A
  • EPS Growth
  • CSBR N/A
  • CABA N/A
  • EPS
  • CSBR 0.46
  • CABA N/A
  • Revenue
  • CSBR $58,591,000.00
  • CABA N/A
  • Revenue This Year
  • CSBR $15.11
  • CABA N/A
  • Revenue Next Year
  • CSBR $7.80
  • CABA N/A
  • P/E Ratio
  • CSBR $12.83
  • CABA N/A
  • Revenue Growth
  • CSBR 19.03
  • CABA N/A
  • 52 Week Low
  • CSBR $3.60
  • CABA $0.99
  • 52 Week High
  • CSBR $11.99
  • CABA $13.50
  • Technical
  • Relative Strength Index (RSI)
  • CSBR 39.89
  • CABA 63.25
  • Support Level
  • CSBR $5.59
  • CABA $1.68
  • Resistance Level
  • CSBR $6.32
  • CABA $2.16
  • Average True Range (ATR)
  • CSBR 0.35
  • CABA 0.19
  • MACD
  • CSBR 0.08
  • CABA 0.03
  • Stochastic Oscillator
  • CSBR 26.67
  • CABA 68.48

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: